Histone Deacetylase (HDAC) Inhibitor and PI3K Inhibitor
CUDC-907 for Pediatric Cancer
This trial is testing a new drug called CUDC-907 to see if it can help children with certain cancers that haven't responded to other treatments. The drug works by blocking proteins that help cancer cells grow. The main goal is to find the safest dose for children and see if the drug has any benefits.
Monoclonal Antibodies
Intra-arterial Cetuximab for Newly Diagnosed Glioblastoma
This trial is a study to see if a new treatment for brain cancer is safe and effective. The new treatment is a combination of standard chemotherapy and radiation therapy, with an additional drug given through a direct infusion into the brain.
Popular Filters
Trials for Diffuse Intrinsic Pontine Glioma Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Checkpoint Inhibitor
Pembrolizumab for Pediatric Brain Cancer
This trial studies the safety and effectiveness of pembrolizumab in younger patients with aggressive or treatment-resistant brain tumors. Pembrolizumab is an immunotherapy drug that helps the immune system attack cancer by blocking a protein that stops immune cells from working effectively. Pembrolizumab has been used in various cancers, showing effective antitumor activity and is approved by the FDA for multiple uses.
Trials for Pituitary Adenomas Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Trials for Metastatic Patients
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Nonsteroidal Anti-inflammatory Drug
Meclofenamate for Brain Cancer
This trial is testing a drug to see if it can prevent brain metastasis growth. This is the first time the drug is being used to treat brain metastasis, and researchers want to see if it's effective and safe.
Phase 3 Trials
Radiation
Stereotactic Radiosurgery vs. HA-WBRT + Memantine for Brain Cancer
This trial is testing whether memantine used in combination with HA-WBRT helps to improve mental function (measured by how well patients can remember things) compared to those who receive HA-WBRT alone.
NMDA receptor antagonist
Memantine for Brain Tumor
This trial tests whether memantine can help children and adolescents with brain tumors maintain their thinking abilities during treatment. Memantine may protect brain function by blocking certain parts of nerve cells that cause thinking problems. Memantine has been used to treat thinking issues in Alzheimer's disease and to prevent thinking problems in patients undergoing brain treatment.
Radiation Therapy
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Brain Metastasis from Lung Cancer
This trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus for the treatment of small cell lung cancer that has spread to the brain.
Alkylating agents
Chemotherapy + Stem Cell Transplant for Brain Cancer
This trial is studying two different chemotherapy combinations to compare how well they work in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma.
Radiation Therapy
Radiosurgery vs Whole Brain Radiation for Brain Metastasis
This trial compares two radiation treatments for brain tumors from non-melanoma cancers. One treatment is a focused, high-dose method, while the other treats the entire brain over several sessions. The goal is to determine which method controls tumors better and has fewer side effects on thinking and memory. The focused, high-dose method has been increasingly used over the past years as an effective treatment for brain metastases, often replacing the whole brain treatment due to its ability to improve outcomes and reduce side effects.
Trials With No Placebo
Chemotherapy
PF-07799544 for Cancer
This trial tests a new cancer medicine, PF-07799544, taken regularly as a tablet. It is for people with advanced solid tumors who haven't responded to other treatments. The medicine may be used alone or with other drugs to improve its effectiveness.
CDK4/6 Inhibitor
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
This trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
Checkpoint Inhibitor
Pembrolizumab for Pediatric Brain Cancer
This trial studies the safety and effectiveness of pembrolizumab in younger patients with aggressive or treatment-resistant brain tumors. Pembrolizumab is an immunotherapy drug that helps the immune system attack cancer by blocking a protein that stops immune cells from working effectively. Pembrolizumab has been used in various cancers, showing effective antitumor activity and is approved by the FDA for multiple uses.
View More Related Trials
Frequently Asked Questions
Introduction to brain cancer
What are the top hospitals conducting brain cancer research?
When it comes to cutting-edge research on brain cancer, several hospitals across the United States are making significant strides. Memorial Sloan Kettering Cancer Center in New york leads the charge with 12 active clinical trials dedicated to brain cancer and a total of 52 completed trials since their first recorded trial in 2003. In Tampa, Moffitt Cancer Center is also at the forefront of brain cancer research, currently conducting nine ongoing clinical trials and having completed 22 studies since their inaugural trial in 2004.
Meanwhile, in Boston's prestigious Dana-Farber Cancer Institute, researchers are actively engaged in nine clinical trials focused on brain cancer. Their commitment extends beyond just current investigations; they have conducted a total of 31 studies since initiating their first trial back in 2002. Wake Forest University Health Sciences in Winston-Salem is another institution that has made significant contributions to advancing our understanding of brain cancer. With eight active trials and a total of sixteen previous studies dating back to their initial trial in 2004, they play an important role within this field.
In Urbana's Carle Cancer Center, while smaller-scale by comparison, researchers are making meaningful progress with six active clinical trials for brain cancer and fourteen completed trials thus far. Their journey started only eighteen years ago when they conducted their first recorded trial focusing on this complex condition.
These hospitals represent beacons of hope for those affected by brain cancer — places where innovative minds come together to unravel its mysteries through rigorous scientific exploration. By pushing boundaries and continuously endeavoring for breakthroughs, these institutions bring us closer to improved treatments and better outcomes for patients worldwide who bravely face this challenging disease every day
Which are the best cities for brain cancer clinical trials?
When it comes to brain cancer clinical trials, several cities emerge as top destinations for cutting-edge research. New york, with 39 active trials, Boston with 34 ongoing studies, and Los Angeles with 23 investigations offer promising opportunities for patients seeking innovative treatments. Additionally, Houston's contributions cannot be overlooked as it hosts 22 active trials focused on glioblastoma multiforme and other potential breakthroughs. Atlanta also presents a significant presence in the field of brain cancer research with its 20 ongoing studies. These cities provide individuals battling brain cancer access to groundbreaking clinical trials that pave the way for advancements in care and hope for improved outcomes.
Which are the top treatments for brain cancer being explored in clinical trials?
Exciting developments are underway in clinical trials as researchers explore new treatments for brain cancer. Nivolumab takes the lead with four active trials and 19 all-time brain cancer trials since its introduction in 2014. Similarly, a pharmacological study shows promise with four ongoing trials and 16 all-time brain cancer trials starting in 2003. Pembrolizumab follows closely behind, involved in three active trials and accumulating an impressive total of 17 all-time brain cancer studies since its listing in 2015. Rounding off the top contenders is stereotactic radiosurgery, currently being tested in three active trials and boasting an extensive history of involvement with a remarkable 37 all-time brain cancer studies dating back to 2004. These advancements offer hope for improved outcomes and brighter futures for patients battling this complex disease.
What are the most recent clinical trials for brain cancer?
Promising advancements are underway in the field of brain cancer research, with recent clinical trials offering hope for patients. One such trial focuses on NovoTTF-200A, a cutting-edge treatment that has progressed to Phase 1 and Phase 2 trials. Another study explores the potential benefits of RRx-001, currently in Phase 1 testing. Additionally, PET/CT and MRI imaging play crucial roles in a Phase 2 trial aimed at enhancing diagnostic capabilities for brain cancer. Furthermore, ongoing investigations into Nivolumab's efficacy through Phase 2 studies demonstrate continued efforts to improve treatment options for this challenging disease. These recent clinical trials signal encouraging progress in the fight against brain cancer and inspire optimism for better outcomes in the future
What brain cancer clinical trials were recently completed?
Recent advancements in brain cancer research have brought about the completion of several noteworthy clinical trials. In October 2020, a trial conducted by Blue Earth Diagnostics explored the potential of 18F fluciclovine as a diagnostic tool for brain cancer. Another trial involving the same sponsor and treatment was completed in August 2020, further contributing to our understanding of its efficacy. Emory University's investigation into WP1066 concluded in May 2020, shedding light on potential therapeutic options for this complex disease. These significant milestones underscore the tireless efforts of researchers striving to find improved treatments and diagnostics for individuals affected by brain cancer.